Abstract: A method of implementing administrative services for managing group feedback is disclosed. A selection of a feedback visibility setting for a feedback message from a plurality of predefined feedback visibility settings is received via a give feedback tab of a user interface. The feedback message and a selection of one or more recipients are received via the give feedback tab. The feedback message is sent to the selected one or more recipients based on the selected feedback visibility setting. A request for feedback and a selection of one or more feedback providers are received via a request feedback tab of the user interface. The request for feedback is sent to the selected one or more feedback providers. Received feedback responses linked to a user profile of the feedback requestor are stored.

Abstract: A method of implementing administrative services for managing status updates is disclosed. A status update configuration window is provided on a graphical user interface. The status update configuration window comprises a plurality of update settings for configuring recurring status updates. A selection of update settings is received in the status update configuration window comprising an update frequency, a set of update questions, and a schedule for update reminders. The selected update settings are stored as an update template. An update summary window is displayed concurrently with the status update configuration window. The update summary window comprises a limited list of one or more selectable update management functions. A selection of an update management function is received from the update summary window.

Abstract: This disclosure provides methods and systems useful in array-based analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics.

Abstract: This disclosure provides methods and systems useful in array-based analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics. The disclosure is based on the hybridisation of amplified fragments from the sample, e.g. a maternal sample, which may employ molecular inversion probes MIP to an oligonucleotide array and the detection of the alleles based on different signals from the different alleles of the SNP.

Abstract: This disclosure provides methods and kits useful in analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications, and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics. The method is based on the hybridization of amplified fragments obtained from the sample, e.g., using molecular inversion probes (MIP) to an oligonucleotide array and the detection of the alleles based on different signals from the different alleles of the SNP.

Abstract: Methods and systems for determining a subject's likelihood of responding to a treatment by assessing the subject's cell-free DNA (cfDNA) sample include receiving sequence data gathered from sequencing the cfDNA sample, generating a feature matrix of values that correspond to synonymous and nonsynonymous mutations detected in the sequence data, and predicting, based on analysis of the feature matrix at a TMB prediction model, a tumor mutational burden (TMB) for a tissue of interest at the subject. The predicted TMB is evaluated to determine whether a set of criteria indicating a likely response to treatment is met. The set of criteria can include criterion(s) that are met when the predicted TMB is high, when the predicted TMB corresponds to a predicted tumoral heterogeneity indicative of homogeneous tissue, when the predicted TMB corresponds to a tumor fraction indicative of a positive responder, or any combination thereof.

Abstract: This disclosure provides methods and kits useful in analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics. The method is based on the hybridisation of amplified fragments obtained from the sample, e.g. using molecular inversion probes (MIP) to an oligonucleotide array and the detection of the alleles based on different signals from the different alleles of the SNP.

Abstract: This disclosure provides methods and kits useful in analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics. The method is based on the hybridisation of amplified fragments obtained from the sample, e.g. using molecular inversion probes (MIP) to an oligonucleotide array and the detection of the alleles based on different signals from the different alleles of the SNP.

Abstract: This disclosure provides methods and systems useful in array-based analysis of mixed nucleic acid populations, including for multiplex genotyping of a mixed nucleic acid sample and for detecting differences in copy number of a target polynucleotide and/or a target chromosome (e.g., microdeletions, duplications and aneuploidies). The disclosure also provides methods and systems useful in the diagnosis of genetic abnormalities in a mixed nucleic acid population taken non-invasively from an organism, such as a sample of blood, plasma, serum, urine stool or saliva. The disclosed methods and systems find use in multiple applications, including prenatal testing and cancer diagnostics. The disclosure is based on the hybridisation of amplified fragments from the sample, e.g. a maternal sample, which may employ molecular inversion probes MIP to an oligonucleotide array and the detection of the alleles based on different signals from the different alleles of the SNP.

Abstract: A system includes an Active Noise Control (ANC) module unit configured to be installed within an air intake or exhaust of a power generation unit. The ANC module unit includes an ANC housing shaped to fit within the air intake or exhaust, an ANC core configured to be secured within the ANC housing, which includes a microphone configured to detect a sound generated by the power generation unit, a control board configured to control the noise-canceling sound based on the sound signal from the microphone and a set of pre-determined noise reduction transfer functions, and a first speaker configured to deliver a first noise-canceling sound to the air intake or exhaust.

Abstract: A serialization service module is provided for configuring an asset management system to provide a secure means of generating, assigning to chips (or other electronic objects or devices), and tracking unique serial numbers. To provide this service, a controller connects through a secure, encrypted connection to appliances at a manufacturer's location. Agents can then request serial number values from an appliance by product name. The serial numbers are generated by the appliance, metered, and provided to the agents. The serial numbers are then injected sequentially into each die in a chip manufacturing process using the agent. A log is reported to the controller.

Abstract: A system includes an Active Noise Control (ANC) module unit configured to be installed within an air intake or exhaust of a power generation unit. The ANC module unit includes an ANC housing shaped to fit within the air intake or exhaust, an ANC core configured to be secured within the ANC housing, which includes a microphone configured to detect a sound generated by the power generation unit, a control board configured to control the noise-canceling sound based on the sound signal from the microphone and a set of pre-determined noise reduction transfer functions, and a first speaker configured to deliver a first noise-canceling sound to the air intake or exhaust.

Abstract: A serialization service module is provided for configuring an asset management system to provide a secure means of generating, assigning to chips (or other electronic objects or devices), and tracking unique serial numbers. To provide this service, a controller connects through a secure, encrypted connection to appliances at a manufacturer's location. Agents can then request serial number values from an appliance by product name. The serial numbers are generated by the appliance, metered, and provided to the agents. The serial numbers are then injected sequentially into each die in a chip manufacturing process using the agent. A log is reported to the controller.

Abstract: A serialization service module is provided for configuring an asset management system to provide a secure means of generating, assigning to chips (or other electronic objects or devices), and tracking unique serial numbers. To provide this service, a controller is used to define a product model, then to define one or more serialization schemas to be bound to each product model. Each serialization schema contains a range of serial numbers for a particular product. The serial number schemas are sent over a secure, encrypted connection to appliances at the manufacturer's location. Agents can then request serial number values by product name. The serial numbers are generated by the appliance, metered, and provided to the agents. The serial numbers are then injected sequentially into each die in a chip manufacturing process using the agent.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: The present invention provides a panel of protein-based biomarkers that are useful in diagnosing ovarian cancer in a subject. In particular, the panel of biomarkers of the invention are useful to classify a subject sample as having ovarian cancer or non-ovarian cancer.

Abstract: A serialization service module is provided for configuring an asset management system to provide a secure means of generating, assigning to chips (or other electronic objects or devices), and tracking unique serial numbers. To provide this service, a controller is used to define a product model, then to define one or more serialization schemas to be bound to each product model. Each serialization schema contains a range of serial numbers for a particular product. The serial number schemas are sent over a secure, encrypted connection to appliances at the manufacturer's location. Agents can then request serial number values by product name. The serial numbers are generated by the appliance, metered, and provided to the agents. The serial numbers are then injected sequentially into each die in a chip manufacturing process using the agent.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.

Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.